Ros1derings : August Edition


The second issue of our newsletter was released just over two weeks ago. For those who have missed it, you can grab it here : Ros1derings : August edition Contents include: A feature about Luna Okada, a 6.5 year ROS1der Some numbers about Xalkori use Fundraising updates Tips for traveling with stage 4 cancer An … Continue reading Ros1derings : August Edition

ROS1 abstracts at #WCLC19


Below are all the abstracts related to ROS1 NSCLC listed in the scientific program for the 2019 IASLC World Conference on Lung Cancer in Barcelona, Spain September 7-10.  While the times and locations of sessions may change, the numbers and names will not.  ES14 – What First Line in Oncogene Addicted NSCLC 15:15 – 16:45 … Continue reading ROS1 abstracts at #WCLC19

Entrectinib -Roche’s Gene-Targeting Drug Shows Promise in Child Brain Tumors


“The young boy was running out of time. His brain tumor was growing so fast that he had trouble putting words together. All standard cancer treatments had failed. Then last summer the child started taking an experimental pill that targeted a rare genetic mutation found inside his tumor. Within months, the malignant growth started to … Continue reading Entrectinib -Roche’s Gene-Targeting Drug Shows Promise in Child Brain Tumors

The ROS1ders Interview Dr. Ross Camidge (16-May-2019)


On May 16, 2019, ROS1der co-founder Janet Freeman-Daily interviewed ROS1 expert D Ross Camidge, MD, PhD, Director of Thoracic Oncology and the Joyce Zeff Chair in Lung Cancer Research at the University of Colorado in a Zoom Webinar. We discussed questions that have arisen among experienced patients in The ROS1ders regarding diagnosis, treatment, and research … Continue reading The ROS1ders Interview Dr. Ross Camidge (16-May-2019)

pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC


Yesterday the pan-Canadian Oncology Drug Review (pCODR) process gave a positive initial recommendation for first-line crizotinib for ROS1+ NSCLC based on clear phase 2 data & Real World Evidence. A randomized Phase 3 study was not required. This is an essential step towards getting crizotinib reimbursed for patients across Canada. This submission was led by … Continue reading pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC